A specific mission:
Provide Easy and Rapid Access to Circulating Rare Cells
ScreenCell was founded with the objective of designing and producing a simple but revolutionary technology allowing the fast and effective isolating of Rare Circulating Cells yielding free of any bias CTC population amenable to better cellular and molecular characterization important in cancer monitoring. This technology also contributes to the development of a new non-invasive approach to prenatal diagnosis.
ScreenCell’s belief is that just enumerating CTCs without easily characterizing them, is not enough to allow the early detection of disease, the discovery of biomarkers to predict treatment responses and potentially the follow-up of disease progression.
ScreenCell designed a full range of devices compatible with existing Invitro Diagnostics (IVD) assays and platforms, with no need for any interface development.